Clinical Trials
41 trialsHAYATE
Bayer
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
Sun Yat-sen University
ROAD
Bayer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
DELINOR
Pfizer
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead4Care
Uppsala University
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
Sun Yat-sen University
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Astellas Pharma Inc
STFREiYTNBC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
BELBEQA
Bayer
CIN
Swami Rama Himalayan University
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
ECHOS
Santa Chiara Hospital
OLIGOMET
Medical University of Vienna
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
Dokuz Eylul University
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
ANCHISES
Azienda Ospedaliero-Universitaria Careggi
To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
Shanghai Zhongshan Hospital
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
Saladax Biomedical, Inc.
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
Cancer Trials Ireland
Multi-academic Center Study of Xofigo Patients
Bayer
Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients
Sun Yat-sen University
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
xenoZ
University of Pisa
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
University of California, San Francisco
Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone
University of Washington
Safety of Xeloda in Solid Tumours
Hoffmann-La Roche
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
Yung Shin Pharm. Ind. Co., Ltd.
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC
Jiangsu ShengDiYa Medicine Co., Ltd.
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
Boehringer Ingelheim
The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
First People's Hospital of Foshan
Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)
Groupe Francais De Pneumo-Cancerologie
PROSTACOX : Metastatic Prostate Chemotherapy
University Hospital, Rouen
OCSTUD
Sanofi
Docetaxel
University of Turku